Genmab A/S Company Top Insiders
| GNMSF Stock | USD 340.00 12.75 3.90% |
Genmab A/S employs about 1.6 K people. The company is managed by 10 executives with a total tenure of roughly 23 years, averaging almost 2.0 years of service per executive, having 156.0 employees per reported executive. Examination of Genmab A/S's management performance can provide insight into the company performance.
| Jan Winkel CEO President and CEO |
| Anthony Pagano President Senior Vice President Global Finance |
Genmab |
Genmab A/S Management Team Effectiveness
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab A/S's management efficiency ratios could be used to measure how well Genmab A/S manages its routine affairs as well as how well it operates its assets and liabilities.Genmab AS has a total of 65.96 Million outstanding shares. 30% of Genmab A/S outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Genmab A/S in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Genmab A/S, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Genmab A/S Workforce Comparison
Genmab AS is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 151,600. Genmab A/S claims roughly 1,560 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38. Genmab A/S Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genmab A/S Price Series Summation is a cross summation of Genmab A/S price series and its benchmark/peer.
Genmab A/S Notable Stakeholders
A Genmab A/S stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Genmab A/S often face trade-offs trying to please all of them. Genmab A/S's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Genmab A/S's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jan Winkel | President and CEO | Profile | |
| Anthony Pagano | Senior Vice President Global Finance | Profile | |
| Tahamtan Ahmadi | Senior Vice President Oncology and Translational Medicine | Profile | |
| Andrew Carlsen | Senior Director, Investor Relations | Profile | |
| Anthony Mancini | Ex COO | Profile | |
| Birgitte MSc | Ex Officer | Profile | |
| Judith MD | Exec Officer | Profile | |
| Peter Ros | Sr Accounting | Profile | |
| Mijke Zachariasse | Director Director | Profile | |
| Rima Nassar | Head VP | Profile |
About Genmab A/S Management Performance
The success or failure of an entity such as Genmab A/S often depends on how effective the management is. Genmab A/S management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genmab management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genmab management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.
Genmab A/S Workforce Analysis
Traditionally, organizations such as Genmab A/S use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genmab A/S within its industry.Genmab A/S Manpower Efficiency
Return on Genmab A/S Manpower
| Revenue Per Employee | 5.4M | |
| Revenue Per Executive | 848.2M | |
| Net Income Per Employee | 1.9M | |
| Net Income Per Executive | 300.8M | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 372.3M |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |